HealthEyePoint’s drug for age-related eye disease fails late-stage trial, shares plunge
EyePoint said its experimental treatment for an age-related eye disease failed to meet the main goal of a late-stage trial. Its shares fell more than 70% on Monday after a few patients lost vision for reasons unrelated to the disease being targeted.
R
Reuters★★☆☆☆2026-08-17 17:01Original
EyePoint’s drug for age-related eye disease fails late-stage trial, shares plunge
Health